CAR T Cell Therapy Market Revenues to exceed USD 15 Billion by 2035 | Roots Analysis

According to our latest market report "CAR-T Cell Therapy Market" by Type of Target Antigen, Type of Target Indication, Key Leading Players, Key Geographical Regions and Sales Forecast: Industry Trends and Global Forecasts, 2024-2035", the global CAR-T cell therapy market size is projected to reach USD 15.2 billion by 2035 from USD 4.6 billion in 2024, growing at a CAGR of 11% in the forecast period 2024-2035.

To request quote of this report, please visit:
https://www.rootsanalysis.com/reports/car-t-therapies-market-2nd-edition-2019-2030/request-quote.html

Amidst the active initiatives undertaken to develop more targeted anti-cancer therapies, CAR-T therapies have emerged as a promising option, given their ability to eradicate tumor cells from the body with minimal treatment-related side effects. Given the consistent increase in number of CAR T cell therapies being developed and launched, the CAR T cell therapy market is on its way to becoming one of the highest valued markets within the biopharmaceutical industry.

CAR-T Cell Therapy Market Segments

Based on the target antigen, the market is segmented into CD 19, BCMA, CD20, CD 19/22 and Others

1. The CD19 target antigen is anticipated to lead the CAR-T cell therapy market, capturing the largest revenue share of more than 65% in 2035.
2. The CD 19 / 22 segment is anticipated to be the fastest growing segment in this industry, with an annualized rate of 75%, during the forecast period.

Based on the target indication, the market is segmented into Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Large B-cell Lymphoma, Mantle Cell Lymphoma, Multiple Myeloma, and Others

1. The multiple myeloma targeting CAR-T cell therapies are anticipated to lead the CAR-T cell therapy market, capturing the largest revenue share of more than 30% in 2034.
2. Market for Acute Myeloid Leukemia is anticipated to be the fastest growing segment in this industry, with an annualized rate of over 45%, during the forecast period.

Based on the Regional Insights, the market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East & North Africa and Rest of the World

1. North America dominated the chimeric antigen receptor T cells therapy market and accounted for the largest revenue share of more than 65% in 2024.
2. In Asia Pacific, the chimeric antigen receptor therapy market is anticipated to demonstrate lucrative growth with an annualized rate of 21%, during the forecast period.

To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/car-t-therapies-market-2nd-edition-2019-2030/request-sample.html

CAR-T Cell Therapy Regional Outlook
Based on the key geographical regions, the CAR-T cell therapy market can be segmented into six major regions, including North America, Europe, Asia Pacific Latin America, Middle East and North Africa, and Rest of the World. North America is anticipated to capture the majority share of the CAR-T cell therapy market in 2024 and this trend is likely to remain unchanged during the forecast period. North America has favorable regulatory environment, strong healthcare infrastructure, and patient advocacy have contributed to its larger market share in CAR T-cell therapy. However, Europe and Asia Pacific hold immense potential for future growth as these regions overcome challenges and invest in infrastructure and regulatory pathways for innovative cancer treatments. Further, the CAR-T drug and therapy industry in Asia-Pacific is accounted to be the fastest-growing segment of the market. The growth of the drug and therapy market in this region is primarily due to the fact that the research and development of CAR-T drugs and therapies in Asia-Pacific is highly favorable in terms of producing high-quality products for global markets.

Key Report Takeaways
1. Currently, over 210 CAR T cell therapy companies are involved in developing potential treatment options for oncological, non-oncological and other disorders. Additionally, players such as CARgen Therapeutics and Kite Pharma (a Gilead Sciences company) are revolutionizing CAR-T therapies manufacturing, driving impactful advancements in healthcare.
2. More than 260 partnerships and collaborations have been inked between several industry / academic stakeholders in order to expedite the development of various pipeline candidates. To fund CAR-T cell therapy development, capital investments worth more than USD 32 billion have been made by various private and public sector investors, in the last few years.
3. According to the cancer data published by the Leukemia and Lymphoma Society in 2023, there were 59,610 new cases of leukemia, along with 89,380 new cases of lymphoma in the US.
4. Based on the regional distribution, North America held 54% market share in 2024 (in terms of revenues generated through sales of approved CAR T cell therapies). Although the process of approval of CAR-T therapies is accelerated through various grants, the high prices of treatment options continue to be one of the key challenges associated with CAR T cell therapy adoption.
5. By 2030, Europe is likely to capture close to 20% share of the global market share.

Browse Full Report Description + Research Methodology + Table of Content + Infographics here:
https://www.rootsanalysis.com/reports/car-t-cell-therapy-market/269.html

CAR-T Cell Therapy Market Key Players
Examples of key companies that offer drugs and therapies for CAR-T cell therapy market CAR-T (which have also been profiled in this market report; the complete list of companies is available in the full report) Autolus, bluebird bio, Bristol Myers Squibb, CARsgen Therapeutics, Cellectis, Gilead Sciences, Innovative Cellular Therapeutics, Noile-Immune Biotech, Novartis, Sinobioway Cell Therapy, Takara Bio and Wellington Zhaotai Therapies

Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com
Website: https://www.rootsanalysis.com

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

This release was published on openPR.